Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Akari Therapeutics (AKTX)

Akari Therapeutics (AKTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Akari Therapeutics Announces New Data from Atopic Keratoconjunctivitis (AKC) Patients Supporting the Potentially Beneficial Role of Nomacopan as an Inhibitor of both C5 and LTB4 in the Ongoing Phase I/II AKC Trial

-- Biopsy tissue expresses the complement C5a receptor 1 and the leukotriene LTB4 receptor BLT1 on and within the surface of the eye, a previously unreported finding

AKTX : 1.74 (+0.58%)
Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress

-- Treatment with nomacopan in six patients in Phase II trial was well tolerated and resulted in rapid onset of clinical improvement in five of six patients

AKTX : 1.74 (+0.58%)
Akari Therapeutics to Participate in Ladenburg Thalmann Healthcare Conference

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene...

AKTX : 1.74 (+0.58%)
Akari's Nomacopan Gets Orphan Drug Tag for Rare Skin Disease

The FDA grants orphan drug status to Akari's (AKTX) nomacopan for the treatment of bullous pemphigoid, a severe blistering skin condition.

ACOR : 2.70 (+5.88%)
ALXN : 101.96 (-2.72%)
EMMA : 2.4500 (-11.23%)
AKTX : 1.74 (+0.58%)
Akari Therapeutics' Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene...

AKTX : 1.74 (+0.58%)
Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More

Key highlights of the past week include litigation updates, acquisitions, and other regulatory and pipeline updates.

SNY : 45.78 (+0.48%)
REGN : 300.58 (-1.07%)
AMGN : 203.38 (-0.63%)
VRTX : 176.52 (+0.22%)
FATE : 14.76 (+0.07%)
ARDX : 4.43 (+0.45%)
AKTX : 1.74 (+0.58%)
Akari Therapeutics to Participate in Citi and H.C. Wainwright Conferences in Early September

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene...

AKTX : 1.74 (+0.58%)
Akari's Nomacopan Gets Orphan Drug Tag for Rare Disease

The FDA assigns an orphan drug status to Akari's (AKTX) nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy, which is a rare disease.

NCNA : 6.25 (-2.19%)
AKTX : 1.74 (+0.58%)
REXN : 1.93 (-6.47%)
EMMA : 2.4500 (-11.23%)
Thinking about buying stock in Aurora Cannabis, Akari Therapeutics, Big Lots, Campbell Soup, or Walt Disney Co?

InvestorsObserver issues critical PriceWatch Alerts for ACB, AKTX, BIG, CPB, and DIS.

AKTX : 1.74 (+0.58%)
ACB.TO : 4.84 (-2.62%)
BIG : 21.73 (-1.85%)
CPB : 47.09 (+1.03%)
DIS : 131.42 (+1.28%)
Akari Therapeutics' Nomacopan Granted U.S. Orphan Drug Designation for Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy (HSCT-TMA)

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene...

AKTX : 1.74 (+0.58%)
Akari Therapeutics Reports Second Quarter 2019 Financial Results And Highlights Recent Clinical Progress

- Positive early safety and efficacy data with nomacopan

AKTX : 1.74 (+0.58%)
Thinking about buying stock in Aurora Cannabis, Akari Therapeutics, Walt Disney Co, Presidio, or Tilray?

InvestorsObserver issues critical PriceWatch Alerts for ACB, AKTX, DIS, PSDO, and TLRY.

AKTX : 1.74 (+0.58%)
ACB.TO : 4.84 (-2.62%)
PSDO : 16.74 (-0.06%)
DIS : 131.42 (+1.28%)
Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)

-- Fast Track designation by the U.S. Food and Drug Administration (FDA) facilitates the development and expedites the review of new medicines like nomacopan that treat serious unmet medical needs and...

AKTX : 1.74 (+0.58%)
Akari Therapeutics announces new data demonstrating synergistic benefits of nomacopan's bifunctional C5 and LTB4 inhibitory activity in pemphigoid disease

-- New data from bullous pemphigoid (BP) patients and pemphigoid disease (PD) models generated by Dr. Christian Sadik's group at University of Lubeck, Germany published in the August 2019 edition of JCI...

AKTX : 1.74 (+0.58%)
Akari Therapeutics Announces Oral Presentation of Nomacopan Phase II Data in Patients with Bullous Pemphigoid at the 28th European Academy of Dermatology and Venereology (EADV) Congress, October 9-13, 2019

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems...

AKTX : 1.74 (+0.58%)
Alexion's Ultomiris Receives EU Approval for PNH in Adults

Alexion (ALXN) obtains approval for its long-acting C5 complement inhibitor, Ultomiris, in Europe for PNH in adults.

AMAG : 11.38 (-0.18%)
ALXN : 101.96 (-2.72%)
ACHN : 6.24 (+70.96%)
AKTX : 1.74 (+0.58%)
Akari Therapeutics, Plc Announces $4.5 Million Registered Direct Offering

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems...

AKTX : 1.74 (+0.58%)
Alexion Receives FDA Approval for Label Expansion of Soliris

Alexion (ALXN) obtains FDA approval for Soliris for the treatment of neuromyelitis optica spectrum disorder.

ALXN : 101.96 (-2.72%)
ACHN : 6.24 (+70.96%)
GILD : 65.62 (+0.49%)
AKTX : 1.74 (+0.58%)
Alexion's sBLA for Ultomiris Gets Priority Review From FDA

The FDA accepts Alexion's (ALXN) sBLA for Ultomiris under priority review for treating atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy. Shares increase.

ALXN : 101.96 (-2.72%)
ACHN : 6.24 (+70.96%)
ACOR : 2.70 (+5.88%)
AKTX : 1.74 (+0.58%)
Akari Therapeutics Reports First Quarter 2019 Financial Results And Highlights Recent Clinical Progress

-- Further clinical data from BP and AKC trials anticipated in 2019

AKTX : 1.74 (+0.58%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI -0.91 , AIZ +0.04 , SBAC -9.22 , SO +0.19 , WELL -0.71
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar